PRAX
HEALTHCAREPraxis Precision Medicines Inc
$338.07+4.77 (+1.43%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PRAX Today?
No stock-specific AI insight has been generated for PRAX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$35.21$356.00
$338.07
Fundamentals
Market Cap$9.4B
P/E Ratio—
EPS$-13.48
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume361K
Avg Volume (10D)—
Shares Outstanding27.9M
PRAX News
20 articles- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 5, 2026
- Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor ConferenceYahoo Finance·May 4, 2026
- Praxis (PRAX) Aligns Pay With Ulixacaltamide Progress Is Incentive Design Now a Key Edge?Yahoo Finance·May 3, 2026
- A Look At Praxis Precision Medicines (PRAX) Valuation After Strong Long Term Shareholder ReturnsYahoo Finance·May 3, 2026
- Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for UlixacaltamideYahoo Finance·Apr 29, 2026
- KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen TherapeuticsYahoo Finance·Apr 28, 2026
- Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in NeurologyYahoo Finance·Apr 27, 2026
- Praxis Precision Medicines (PRAX): One of the Best Upside StocksYahoo Finance·Apr 23, 2026
- FDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws FocusYahoo Finance·Apr 21, 2026
- Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish BreakoutYahoo Finance·Apr 14, 2026
- Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorYahoo Finance·Apr 14, 2026
- Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026Yahoo Finance·Apr 13, 2026
- Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic EncephalopathyGlobeNewswire Inc.·Apr 6, 2026
- A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For RelutrigineYahoo Finance·Apr 5, 2026
- Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEsYahoo Finance·Mar 30, 2026
- Structure Therapeutics Slides 28% This Year as $6 Million Stake EmergesMotley Fool·Mar 22, 2026
- Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million ExitMotley Fool·Mar 18, 2026
- Will Extended Cash Runway And Dual FDA Filings Shift Praxis Precision Medicines' (PRAX) Narrative Toward Commercialization?Yahoo Finance·Mar 18, 2026
- Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended RunwayYahoo Finance·Mar 18, 2026
All 20 articles loaded
Price Data
Open$335.23
Previous Close$333.30
Day High$340.21
Day Low$323.30
52 Week High$356.00
52 Week Low$35.21
52-Week Range
$35.21$356.00
$338.07
Fundamentals
Market Cap$9.4B
P/E Ratio—
EPS$-13.48
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume361K
Avg Volume (10D)—
Shares Outstanding27.9M
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—